ARTL earnings date and last-quarter result: next report 2026-08-12, last quarter miss, P/E -0.12. Updated 2026-07-23.
Artelo Biosciences (ARTL) Research Hub
Artelo Biosciences (ARTL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.2 USD (-13.73%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.12, market cap 0.00B. This hub links to the full technical, earnings and options research available for ARTL.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.2 USD (-13.73%) |
| 52-week range | 2.15 USD – 15.73 USD |
| Trend regime | Range |
| 14-day RSI | 0 (Oversold) |
| Trailing P/E | -0.12 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for ARTL
Covered Call on ARTL: how it works, illustrative setup around the real 2.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ARTL: how it works, illustrative setup around the real 2.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ARTL: how it works, illustrative setup around the real 2.2 USD price, max profit/loss, breakeven and when to use it. Educational.
ARTL technical analysis: range, last 2.2 USD, RSI 0, 52w range 2.15 USD–15.73 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ARTL in?
Artelo Biosciences (ARTL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ARTL in an uptrend or downtrend?
As of 2026-10-26, ARTL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ARTL's trailing P/E ratio?
ARTL's trailing P/E is -0.12, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does ARTL next report earnings?
ARTL is next scheduled to report earnings on 2026-08-12.